Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S36, 2019. DOI: 10.25251/skin.3.supp.36. Disponível em: https://skin.dermsquared.com/skin/article/view/763. Acesso em: 19 apr. 2025.